Prostate Cancer Treatment Guidelines

Introduction to Prostate Cancer Treatment

The European Society for Medical Oncology recommends against using any repurposed medications, including metformin, for prostate cancer treatment due to lack of survival benefit 1, 2, 3, 4, 5, 6, 7

For metastatic hormone-sensitive prostate cancer, the American Society of Clinical Oncology suggests evidence-based options including ADT plus docetaxel for fit patients with high-volume disease 4, 5, 6
The European Association of Urology recommends ADT plus novel hormone agents, such as abiraterone, enzalutamide, apalutamide, or darolutamide, for metastatic hormone-sensitive prostate cancer 4, 5, 6, 7
The National Comprehensive Cancer Network suggests triplet therapy, consisting of ADT, docetaxel, and abiraterone or darolutamide, for fit patients with de novo metastatic disease 5, 6, 7

For castration-resistant prostate cancer, the European Society for Medical Oncology recommends abiraterone or enzalutamide for chemotherapy-naïve patients 1, 2, 3
The American Society of Clinical Oncology suggests olaparib for patients with BRCA1/2 alterations after androgen receptor axis inhibitors 5, 6, 7
The European Association of Urology recommends 177Lu-PSMA-617 for patients with PSMA-expressing tumors after taxane and novel androgen receptor axis inhibitor 5, 6, 7